Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Ndjeka

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
The Lancet. Respiratory Medicine|January 11, 2019
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis - Authors' replyNorbert Ndjeka,
The Lancet. Global Health|August 22, 2025
The high cost of donor withdrawal: implications for tuberculosis progressNorbert Ndjeka, Jody Boffa
The Lancet. Infectious Diseases|February 9, 2025
Cash incentives as a bold new strategy for tuberculosis controlNorbert Ndjeka, Waasila Jassat
The Lancet. Infectious Diseases|March 26, 2023
Balancing adjunctive therapy for tuberculosis treatmentNorbert Ndjeka, Jennifer Furin
The Lancet. Microbe|May 11, 2022
Bedaquiline and clofazimine: successes and challengesNorbert Ndjeka, Nazir A Ismail
Applied Health Economics and Health Policy|October 6, 2017
Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based AnalysisKathryn Schnippel, Cynthia Firnhaber, Francesca Conradie, et al.
The Lancet. Infectious Diseases|December 12, 2018
Multidrug-resistant tuberculosis outbreak in South AfricaNazir A Ismail, Kerrigan McCarthy, Francesca Conradie, et al.
The New England Journal of Medicine|January 5, 2022
Bedaquiline-Resistant Tuberculosis Associated with <i>Rv0678</i> MutationsShaheed V Omar, Farzana Ismail, Norbert Ndjeka, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 12, 2015
Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case registerKathryn Schnippel, Kate Shearer, Denise Evans, et al.
Plos Medicine|October 19, 2019
Advances in clinical trial design for development of new TB treatments-Translating international tuberculosis treatment guidelines into national strategic plans: Experiences from Belarus, South Africa, and VietnamGrania Brigden, Nguyen Viet Nhung, Alena Skrahina, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
The Lancet. Respiratory Medicine|January 11, 2019
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis - Authors' replyNorbert Ndjeka,
The Lancet. Global Health|August 22, 2025
The high cost of donor withdrawal: implications for tuberculosis progressNorbert Ndjeka, Jody Boffa
The Lancet. Infectious Diseases|February 9, 2025
Cash incentives as a bold new strategy for tuberculosis controlNorbert Ndjeka, Waasila Jassat
The Lancet. Infectious Diseases|March 26, 2023
Balancing adjunctive therapy for tuberculosis treatmentNorbert Ndjeka, Jennifer Furin
The Lancet. Microbe|May 11, 2022
Bedaquiline and clofazimine: successes and challengesNorbert Ndjeka, Nazir A Ismail
Applied Health Economics and Health Policy|October 6, 2017
Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based AnalysisKathryn Schnippel, Cynthia Firnhaber, Francesca Conradie, et al.
The Lancet. Infectious Diseases|December 12, 2018
Multidrug-resistant tuberculosis outbreak in South AfricaNazir A Ismail, Kerrigan McCarthy, Francesca Conradie, et al.
The New England Journal of Medicine|January 5, 2022
Bedaquiline-Resistant Tuberculosis Associated with <i>Rv0678</i> MutationsShaheed V Omar, Farzana Ismail, Norbert Ndjeka, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 12, 2015
Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case registerKathryn Schnippel, Kate Shearer, Denise Evans, et al.
Plos Medicine|October 19, 2019
Advances in clinical trial design for development of new TB treatments-Translating international tuberculosis treatment guidelines into national strategic plans: Experiences from Belarus, South Africa, and VietnamGrania Brigden, Nguyen Viet Nhung, Alena Skrahina, et al.
Pageof 6